Table 2. Stratified7+cyclin D1 expression and overall survival of HCC patients.
Variable | Total number |
MCM7highor cyclin D1high |
MCM7low
and cyclin D1low |
HR (95% CI)a | P-valuea | ||
---|---|---|---|---|---|---|---|
Case number | MST (month) | Case number | MST (month) | ||||
Overall | 153 | 87 | 25.0 | 66 | >63.0 | 2.57 (1.61–4.10) | <0.001 |
Age | |||||||
⩽55 years | 93 | 51 | 25.0 | 42 | 48.0 | 2.43 (1.36–4.33) | 0.003 |
> 55 years | 60 | 36 | 24.0 | 24 | >63.0 | 2.72 (1.22–6.06) | 0.015 |
Gender | |||||||
Male | 101 | 57 | 20.0 | 44 | >63.0 | 2.70 (1.46–5.01) | 0.002 |
Female | 52 | 30 | 26.0 | 22 | 46.0 | 2.61 (1.26–5.39) | 0.01 |
Hepatitis virus infection | |||||||
Negative | 43 | 23 | 31.0 | 20 | >63.0 | 3.73 (1.23–11.36) | 0.02 |
Positive | 110 | 64 | 17.0 | 46 | 46.0 | 2.37 (1.41–3.99) | 0.001 |
Cirrhosis | |||||||
Absent | 55 | 28 | 42.0 | 27 | >62.0 | 2.45 (1.00–6.01) | 0.051 |
Present | 98 | 59 | 15.0 | 39 | 48.0 | 2.54 (1.46–4.40) | 0.001 |
Child–Pugh score | |||||||
A+B | 142 | 80 | 26.0 | 62 | >63.0 | 2.53 (1.55–4.12) | <0.001 |
C | 11 | 7 | 18.0 | 4 | 46.0 | 4.84 (0.57–40.86) | 0.147 |
Serum AFP level | |||||||
<200 ng/ml | 76 | 37 | 31.0 | 39 | >63.0 | 3.02 (1.47–6.23) | 0.003 |
⩾200 ng/ml | 77 | 50 | 13.0 | 27 | 37.0 | 1.95 (1.05–3.60) | 0.034 |
Tumor size | |||||||
⩽5 cm | 99 | 50 | 28.0 | 49 | >63.0 | 2.74 (1.49–5.05) | 0.001 |
>5 cm | 54 | 37 | 17.0 | 17 | 30.0 | 1.86 (0.88–3.94) | 0.105 |
Tumor number | |||||||
Single | 103 | 56 | 24.0 | 47 | >63.0 | 3.21 (1.77–5.83) | <0.001 |
Multiple (⩾2) | 50 | 31 | 28.0 | 19 | 46.0 | 1.58 (0.74–3.38) | 0.235 |
Capsule integrity | |||||||
Yes | 70 | 40 | 24.0 | 30 | >63.0 | 2.60 (1.33–5.11) | 0.005 |
No | 83 | 47 | 25.0 | 36 | 48.0 | 2.47 (1.29–4.74) | 0.006 |
Venous invasion | |||||||
Negative | 111 | 53 | 28.0 | 58 | >63.0 | 2.53 (1.47–4.36) | 0.001 |
Positive | 42 | 34 | 13.0 | 8 | 16.0 | 1.61 (0.56–4.62) | 0.375 |
Differentiation | |||||||
Edmonson I–II | 82 | 34 | 32.0 | 48 | >63.0 | 2.25 (1.13–4.48) | 0.021 |
Edmonson III–IV | 71 | 53 | 22.0 | 18 | 37.0 | 1.82 (0.92–3.64) | 0.088 |
TNM stage | |||||||
I+II | 112 | 55 | 28.0 | 57 | >63.0 | 2.53 (1.45–4.40) | 0.001 |
III | 41 | 32 | 13.0 | 9 | 26.0 | 1.60 (0.61–4.19) | 0.337 |
BCLC stage | |||||||
A–B | 106 | 52 | 28.0 | 54 | >63.0 | 2.71 (1.55–4.75) | 0.001 |
C | 47 | 35 | 17.0 | 12 | 46.0 | 1.67 (0.69–4.06) | 0.259 |
Abbreviations: CI, confidence interval; HR, hazard ratio; MST, median survival time
HR and P-value were derived from univariate analysis. The significant P-values (<0.05) are in bold